106 related articles for article (PubMed ID: 14739663)
1. Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol.
van den Bongard HJ; Sparidans RW; Critchley DJ; Beijnen JH; Schellens JH
Invest New Drugs; 2004 Apr; 22(2):151-8. PubMed ID: 14739663
[TBL] [Abstract][Full Text] [Related]
2. In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood.
Bongard HJ; Pluim D; Waardenburg RC; Ravic M; Beijnen JH; Schellens JH
Anticancer Drugs; 2003 Jul; 14(6):405-10. PubMed ID: 12853880
[TBL] [Abstract][Full Text] [Related]
3. An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients.
van sen Bongard HJ; Pluim D; Rosing H; Nan-Offeringa L; Schot M; Ravic M; Schellens JH; Beijnen JH
Anticancer Drugs; 2002 Sep; 13(8):807-14. PubMed ID: 12394264
[TBL] [Abstract][Full Text] [Related]
4. The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol.
Sunkara G; Bigler H; Wang Y; Smith H; Prasad P; McLeod J; Ligueros-Saylan M
Curr Med Res Opin; 2004 Jan; 20(1):41-8. PubMed ID: 14741071
[TBL] [Abstract][Full Text] [Related]
5. Phase I pharmacokinetic and pharmacogenomic study of E7070 administered once every 21 days.
Yamada Y; Yamamoto N; Shimoyama T; Horiike A; Fujisaka Y; Takayama K; Sakamoto T; Nishioka Y; Yasuda S; Tamura T
Cancer Sci; 2005 Oct; 96(10):721-8. PubMed ID: 16232205
[TBL] [Abstract][Full Text] [Related]
6. Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.
Dittrich C; Dumez H; Calvert H; Hanauske A; Faber M; Wanders J; Yule M; Ravic M; Fumoleau P
Clin Cancer Res; 2003 Nov; 9(14):5195-204. PubMed ID: 14613999
[TBL] [Abstract][Full Text] [Related]
7. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype.
Thijssen HH; Ritzen B
Clin Pharmacol Ther; 2003 Jul; 74(1):61-8. PubMed ID: 12844136
[TBL] [Abstract][Full Text] [Related]
8. Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants.
Kohl C; Steinkellner M
Drug Metab Dispos; 2000 Feb; 28(2):161-8. PubMed ID: 10640513
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation.
Van Kesteren Ch; Mathôt RA; Raymond E; Armand JP; Dittrich Ch; Dumez H; Roché H; Droz JP; Punt C; Ravic M; Wanders J; Beijnen JH; Fumoleau P; Schellens JH;
J Clin Oncol; 2002 Oct; 20(19):4065-73. PubMed ID: 12351604
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes.
Thijssen HH; Flinois JP; Beaune PH
Drug Metab Dispos; 2000 Nov; 28(11):1284-90. PubMed ID: 11038154
[TBL] [Abstract][Full Text] [Related]
11. Stereoselective interaction between piroxicam and acenocoumarol.
Bonnabry P; Desmeules J; Rudaz S; Leemann T; Veuthey JL; Dayer P
Br J Clin Pharmacol; 1996 Jun; 41(6):525-30. PubMed ID: 8799517
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide).
van Kesteren C; Mathôt RA; Raymond E; Armand JP; Fumoleau P; Punt C; Ravic M; Wanders J; Beijnen JH; Schellens JH;
Br J Clin Pharmacol; 2002 Nov; 54(5):463-71. PubMed ID: 12445024
[TBL] [Abstract][Full Text] [Related]
13. A placebo-controlled pharmacodynamic and pharmacokinetic interaction study between tamsulosin and acenocoumarol.
Rolan P; Terpstra IJ; Clarke C; Mullins F; Visser JN
Br J Clin Pharmacol; 2003 Mar; 55(3):314-6. PubMed ID: 12630984
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer.
Raymond E; ten Bokkel Huinink WW; Taïeb J; Beijnen JH; Faivre S; Wanders J; Ravic M; Fumoleau P; Armand JP; Schellens JH;
J Clin Oncol; 2002 Aug; 20(16):3508-21. PubMed ID: 12177112
[TBL] [Abstract][Full Text] [Related]
15. No effect of short-term omeprazole intake on acenocoumarol pharmacokinetics and pharmacodynamics.
de Hoon JN; Thijssen HH; Beysens AJ; Van Bortel LM
Br J Clin Pharmacol; 1997 Oct; 44(4):399-401. PubMed ID: 9354316
[TBL] [Abstract][Full Text] [Related]
16. Investigation of PK-PD drug-drug interaction between acenocoumarol and amoxicillin plus clavulanic acid.
Delavenne X; Laporte S; Demasles S; Mallouk N; Basset T; Tod M; Girard P; Mismetti P
Fundam Clin Pharmacol; 2009 Feb; 23(1):127-35. PubMed ID: 19267776
[TBL] [Abstract][Full Text] [Related]
17. Potential interaction between acenocoumarol and diclofenac, naproxen and ibuprofen and role of CYP2C9 genotype.
van Dijk KN; Plat AW; van Dijk AA; Piersma-Wichers M; de Vries-Bots AM; Slomp J; de Jong-van den Berg LT; Brouwers JR
Thromb Haemost; 2004 Jan; 91(1):95-101. PubMed ID: 14691574
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation.
Tàssies D; Freire C; Pijoan J; Maragall S; Monteagudo J; Ordinas A; Reverter JC
Haematologica; 2002 Nov; 87(11):1185-91. PubMed ID: 12414349
[TBL] [Abstract][Full Text] [Related]
19. Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3.
Thijssen HH; Drittij MJ; Vervoort LM; de Vries-Hanje JC
Clin Pharmacol Ther; 2001 Sep; 70(3):292-8. PubMed ID: 11557918
[TBL] [Abstract][Full Text] [Related]
20. An in vitro evaluation of the victim and perpetrator potential of the anticancer agent laromustine (VNP40101M), based on reaction phenotyping and inhibition and induction of cytochrome P450 enzymes.
Nassar AE; King I; Paris BL; Haupt L; Ndikum-Moffor F; Campbell R; Usuki E; Skibbe J; Brobst D; Ogilvie BW; Parkinson A
Drug Metab Dispos; 2009 Sep; 37(9):1922-30. PubMed ID: 19520774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
